All In Biotech

Drug Trial Radar · NCT06348199

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 (Proposed Pembrolizumab Biosimilar) and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 555 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

555

Actual

Start

Mar 12, 2024

Primary completion

Mar 10, 2026

Study completion Aug 2027

Sponsor

Lead sponsor
Samsung Bioepis Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is: • How effective the study drug is Participants will receive either investigational product (SB27 or Keytruda) and chemotherapy every 3 weeks. Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda.

Conditions

  • Non-small Cell Lung Cancer Stage IV

Interventions

  • SB27Drug

    Will be administered intravenously at a fixed dose of 200 mg every 3 weeks

  • KeytrudaDrug

    Will be administered intravenously at a fixed dose of 200 mg every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) at Week 24Time frame: At Week 24

Locations

93 sites in 14 countries. Site status is shown where the registry gives one.

  • SB Investigative Site

    Banja Luka, Bosnia and Herzegovina

  • SB Investigative Site

    Mostar, Bosnia and Herzegovina

  • SB Investigative Site

    Sarajevo, Bosnia and Herzegovina

  • SB Investigative Site

    Curitiba, Brazil

  • SB Investigative Site

    Florianópolis, Brazil

  • SB Investigative Site

    Ijuí, Brazil

  • SB Investigative Site

    Natal, Brazil

  • SB Investigative Site

    Pelotas, Brazil

  • SB Investigative Site 1

    Porto Alegre, Brazil

  • SB Investigative Site 2

    Porto Alegre, Brazil

  • SB Investigative Site

    Rio de Janeiro, Brazil

  • SB Investigative Site

    Santo André, Brazil

  • SB Investigative Site

    Batumi, Georgia

  • SB Investigative Site 1

    Tbilisi, Georgia

  • SB Investigative Site 2

    Tbilisi, Georgia

  • SB Investigative Site 3

    Tbilisi, Georgia

  • SB Investigative Site 4

    Tbilisi, Georgia

  • SB Investigative Site 5

    Tbilisi, Georgia

  • SB Investigative Site 6

    Tbilisi, Georgia

  • SB Investigative Site

    Düsseldorf, Germany

  • SB Investigative Site

    Halle, Germany

  • SB Investigative Site

    Moers, Germany

  • SB Investigative Site

    Neuss, Germany

  • SB Investigative Site

    Bangalore, India

  • SB Investigative Site

    Bhubaneswar, India

  • SB Investigative Site

    Erandwane, India

  • SB Investigative Site

    Hyderabad, India

  • SB Investigative Site 1

    Jaipur, India

  • SB Investigative Site 2

    Jaipur, India

  • SB Investigative Site

    Mumbai, India

  • SB Investigative Site

    Sūrat, India

  • SB Investigative Site

    Udaipur, India

  • SB Investigative Site

    Himeji, Japan

  • SB Investigative Site

    Iwakuni, Japan

  • SB Investigative Site

    Izumi, Japan

  • SB Investigative Site

    Kawachi-Nagano, Japan

  • SB Investigative Site

    Kobe, Japan

  • SB Investigative Site

    Kochi, Japan

  • SB Investigative Site

    Sagamihara, Japan

  • SB Investigative Site

    Tachikawa, Japan

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.